Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05536037 · ClinicalTrials.gov registry record · Phase 1
Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions
A Phase 1 study, sponsored by Thomas Jefferson University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT05536037 is a Phase 1 study that was terminated before completion, run by Thomas Jefferson University. The registered enrollment target is 4 participants.
The verdict
NCT05536037, a Phase 1 study, was terminated before completion, sponsored by Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase I trial tests whether metformin works in reducing the annual transformation (development of invasive cancer) of oral precancerous lesions into cancerous lesions. Metformin is a drug approved for the treatment of diabetes, but studies have shown that it may have some anticancer properties. Giving metformin may help prevent or slow the development of oral cancer from precancerous lesions.
Interventions
- PROCEDURE Biopsy
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-05-04 |
| Est. Completion | 2024-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05536037
The ClinicalTrials.gov registry entry for NCT05536037 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biopsy is the first listed.
NCT05536037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05536037 about?
NCT05536037 is a clinical study titled "Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions". This phase I trial tests whether metformin works in reducing the annual transformation (development of invasive cancer) of oral precancerous lesions into cancerous lesions. Metformin is a drug approved for the treatment of diabetes, but studies have shown that it may have some anticancer properties....
What is the current status of trial NCT05536037?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2022-05-04. Estimated completion is 2024-03-16.
What interventions are being tested in trial NCT05536037?
The interventions under investigation include: Biopsy (PROCEDURE), Metformin (DRUG).
Who is sponsoring clinical trial NCT05536037?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.